Keratoacanthoma
☆ AI Dermatology — Free Service
I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
Masani Keratoacanthoma
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) o se tuma pa'u e masani ona iloa ona o lona tuputupu a'e vave ma e mafai ona toe solomuli na'o ia. E masani lava ona tupu i tama matutua, aulelei-pa'u, ma i tala faasolopito o le la. E ui i le ta'otoga aveese e fa'aaogaina le Mohs micrographic taotoga, o le togafitiga masani, e tele isi togafitiga e avanoa.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) o se tuma maualalo e amata i nisi ga'o i totonu o le pa'u ma foliga tutusa ma le squamous cell carcinoma (SCC) i lalo o le microscope. O loʻo faʻaaauau pea felafolafoaiga pe tatau ona faʻavasega KA o se ituaiga o SCC osofaʻi.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) o le ituaiga lona lua e sili ona taatele o le kanesa i tagata, aemaise lava i tagata matutua. O le taotoga e masani ona faʻaaogaina e togafitia ai le cSCC, ae mo nisi o gasegase e le mafai ona faia se taotoga po o le filifili e le faia, o isi filifiliga e pei o togafitiga faʻapitoa e mafai ona mafaufauina. Togafitiga fa'aleaganu'u (methotrexate or 5-fluorouracil) ua fa'aaogaina, ae o lo'o fa'aauau pea su'esu'ega i auala fou e pei o le tui ma le oncolytic virotherapy. I lenei vaega, o le a tatou va'ava'i i togafitiga faʻapitoa mo le cSCC, e amata mai i auala masani e o'o atu i taiala sili.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
I lalo o le microscope, keratoacanthoma e matua faʻatusalia i le squamous cell carcinoma. Aʻo faʻavasega, e manatu nisi o fomaʻi o le keratoacanthoma o se vaega maʻoti, e le o se faʻamaʻi; e tusa ma le 6 % o faʻamaʻi ma tala faʻasolopito keratoacanthoma o loʻo faʻaalia i le faʻaoso faʻamaʻi ma le mataʻutia o le squamous cell carcinoma.
○ Suiga ma Togafiti
#Dermoscopy
#Skin biopsy